FLT3 and acute myeloid leukemia: As monotherapy, sorafenib has been widely used as salvage therapy for R/R FLT3-ITD AML with a rate of combined complete remission (CR) and CR with incomplete haematologic recovery (CRi) at about 16%–46%.